Drug Research Information Bulletin - Efficacy of AQUAFLOR® (50% Florfenicol) to Control Mortality in Freshwater-Reared Salmonids Diagnosed with Systemic Columnaris Disease

In 2012, supplemental approvals for AQUAFLOR® were granted by FDA and included treatment to control mortality of all warmwater finfish due to streptococcal disease (associated with Streptococcus iniae), and based in part by data reported in the bulletin, to control mortality caused by systemic columnaris in all freshwater finfish. In this bulletin, we summarize the results from two trials that were conducted to support FDA-approval of AQUAFLOR® to control mortality in freshwater-reared salmonids diagnosed with systemic columnaris.